BTCY
Biotricity Inc

824
Mkt Cap
$7.69M
Volume
112,687.00
52W High
$0.8334
52W Low
$0.225
PE Ratio
-1.46
BTCY Fundamentals
Price
$0.2889
Prev Close
$0.275
Open
$0.26
50D MA
$0.4829
Beta
3.07
Avg. Volume
22,270.21
EPS (Annual)
-$0.5548
P/B
-0.22
Rev/Employee
$299,789.00
Loading...
Loading...
News
all
press releases
The Zacks Analyst Blog Highlights Hims & Hers Health, Biotricity and Privia Health
Hims & Hers leads three healthcare IT stocks up over 20% in 2025, as digital care, remote monitoring and data platforms gain traction.
Zacks·6d ago
News Placeholder
More News
News Placeholder
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Zacks·7d ago
News Placeholder
Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates
Biotricity (BTCY) delivered earnings and revenue surprises of +62.50% and -0.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +15.00% and +4.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +158.33% and +3.47%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) delivered earnings and revenue surprises of +18.42% and +6.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
iRhythm Technologies (IRTC) Reports Q3 Loss, Beats Revenue Estimates
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of +83.33% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging Biotricity (BTCY) This Year?
Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Zacks·4mo ago
News Placeholder
Biotricity (BTCY) Upgraded to Buy: Here's Why
Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·5mo ago
<
1
2
...
>

Latest BTCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.